ArticleAnnals of surgical oncology2025
The Function and Clinical Significance of TRPV2 in Human Colon Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundTransient receptor potential vanilloid 2 (TRPV2) is a calcium channel involved in signaling pathways that control cell proliferation, the cell cycle, and apoptosis. The relationship between TRPV2 expression and prognosis has been reported in cancers of various organs. However, the functions and clinical significance of TRPV2 in colon cancer (CC) remain unclear. This study aimed to investigate the role of TRPV2 in CC.
methodsAfter small interfering RNA-induced TRPV2 knockdown in CC cells, we examined the effects on cell proliferation, cell cycle, apoptosis, and wound-healing. Gene expression profiles of CC cells were examined using microarray analysis. Immunohistochemistry of TRPV2 expression was performed on samples from 200 patients who underwent radical colectomy. The patients were divided into two groups according to TRPV2 expression, and their clinicopathologic background and prognosis were analyzed.
resultsThe study showed that TRPV2-depleted CC cells reduced cell proliferation and migration, together with the induction of apoptosis. Based on the cell cycle assay, the transition from the G1 to the S phase was suppressed in the cell cycle. The microarray analysis showed that TRPV2 was involved in PI3K/AKT-, ERK/MAPK-, and role of tissue factor in cancer-signaling pathways. Immunohistochemical analysis showed that high TRPV2 expression was an independent poor prognostic factor (p = 0.016; hazard ratio, 2.045).
conclusionsThe study findings suggested that TRPV2 controls the proliferation, apoptosis, and migration of CC cells. Furthermore, the study identified high TRPV2 expression as a poor prognostic factor for patients with CC.
Identifiers
40830734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.